Steven Romano, a board-certified psychiatrist, has joined by board of Silence Therapeutics Plc as a non-executive director to help oversee the company’s RNA therapeutics for the treatment of serious diseases. Dr Romano is the chief scientific officer at Mallinckrodt Pharmaceuticals Ltd where he has responsibility for research and development and medical and regulatory affairs. Prior to Mallinckrodt, he was an executive at Pfizer Inc. Dr Romano received his medical degree from the University of Missouri-Columbia, US.
Silence Therapeutics Plc announced the appointment on 29 July 2019.
Copyright 2019 Evernow Publishing Ltd.